Milk Thistle: Traditional Use, Constituents and Evidence

My nan kept a scruffy, sun-bleached copy of Culpeper's Complete Herbal on the kitchen windowsill , spine cracked, pages stained with what I now assume was elderberry. Milk thistle got its own dog-eared page. She called it "the liver herb" in the same matter-of-fact tone she used for "put a dock leaf on it." Two thousand years of recorded use will do that to a plant's reputation. But reputation and evidence are different things, and it's worth being careful about conflating them , a lesson that applies to the entire field of phytomedicine.

A brief history of Silybum marianum

Milk thistle (Silybum marianum) is native to the Mediterranean basin and has been naturalised across much of Australia, where it now grows as a common roadside weed. You'll find it along roadsides throughout the Adelaide Hills and across many parts of rural South Australia , those distinctive purple flower heads and white-veined leaves are hard to miss once you know them.

Its recorded medicinal use stretches back to the first century CE. Pliny the Elder described a preparation of the juice mixed with honey as a remedy for "carrying off bile." Dioscorides included it in De Materia Medica. European herbalists of the 16th and 17th centuries, including Culpeper himself, consistently associated it with the liver and spleen. By the 19th century it was a fixture in both German and British herbal practice, and German phytomedicine researchers in the mid-20th century began the systematic chemistry work that would eventually isolate the plant's most studied constituent group: the silymarin flavonolignans.

Key constituents: silymarin and beyond

The term "silymarin" is often used loosely to mean a single compound, but it actually refers to a complex of related flavonolignans extracted primarily from the seeds and fruit of S. marianum. The major components are silybin (also written silibinin), isosilybin, silydianin, and silychristin. Silybin is typically the most abundant and has been the most extensively studied in isolation.

These flavonolignans are formed biosynthetically from the condensation of a flavonoid (taxifolin) with a phenylpropanoid (coniferyl alcohol), producing a structurally unusual bicyclic compound. That structural specificity matters because it influences how the molecules behave in biological systems; including their absorption and bioavailability, which is notoriously poor when silymarin is taken orally as a standard extract. Researchers have explored phospholipid complexes and other formulation strategies specifically to address this limitation, with varying results across published studies.

Beyond silymarin, the plant contains other flavonoids (including quercetin and kaempferol), fatty acids, sterols, and small amounts of tocopherols. Whether these play any meaningful synergistic role, something analogous to what's discussed in the cannabis literature as the entourage effect, is an interesting open question in the phytochemistry research, but it remains underexplored in peer-reviewed work specific to milk thistle.

The quality and concentration of silymarin varies enormously between raw plant material and finished products. This is where the concept of a standardised extract becomes relevant: reputable preparations specify silymarin content as a percentage of the extract dry weight (commonly 70–80%), giving at least some basis for comparing doses across studies. Extracts that don't disclose this figure are difficult to evaluate scientifically or clinically.

What the research has examined

The honest answer is: a lot has been examined, and the results are more complicated than either advocates or sceptics tend to acknowledge.

Preclinical research; cell cultures and animal models, has characterised several mechanisms by which silybin interacts with biological systems. These include modulation of certain enzyme pathways involved in oxidative stress responses, effects on inflammatory signalling cascades (including NF-κB pathway interactions), and some influence on membrane permeability. These are mechanistic observations, not therapeutic claims. Mechanisms identified in cell lines don't automatically translate to the same effects in whole humans, and this is a limitation the research itself consistently flags.

Clinical trial data is more mixed. A Cochrane-style systematic review published in recent years found that while a number of randomised controlled trials have examined milk thistle preparations in the context of liver disease markers, the trials have significant heterogeneity problems: different extract types, variable silymarin concentrations, inconsistent outcome measures, and frequently short durations. The reviewers consistently noted insufficient evidence to draw firm conclusions. That's not a dismissal, it's an honest statement about where the evidence currently sits.

The pharmacokinetics of silybin are genuinely interesting to researchers. It is metabolised via glucuronidation and sulphation, undergoes enterohepatic recirculation, and; critically, is subject to significant first-pass metabolism that reduces systemic exposure after oral dosing. This is part of why oral bioavailability studies report widely varying plasma levels, and why some researchers have argued that achieving pharmacologically relevant concentrations in humans through standard oral preparations may be harder than the preclinical data implies.

How milk thistle sits within Australian regulation

In Australia, complementary medicines containing milk thistle (silymarin) are listed on the Australian Register of Therapeutic Goods, the ARTG; as Listed medicines (ARTG List category) rather than Registered medicines. This distinction matters. Listed medicines are assessed by the TGA for safety and quality but not independently evaluated for efficacy before they enter the market. Manufacturers are permitted to make only "low-level" indications that are pre-approved by the TGA; claims that a product treats or manages a specific disease are not permitted for Listed products without substantiation meeting the Registered medicine standard.

The Therapeutic Goods Act 1989 and the associated Therapeutic Goods (Permissible Indications) Determination set out what Listed complementary medicine sponsors can and cannot say. If you see an Australian product making a specific disease treatment claim for a milk thistle product, that's worth scrutinising, it may not align with what the listing actually permits. The TGA does conduct post-market audits of Listed medicines, including compliance with the permissible indications framework.

Milk thistle itself is not a scheduled substance under the Poisons Standard (unlike some other traditional herbal preparations, such as kava, which carries specific import controls under the Customs (Prohibited Imports) Regulations 1956 and requires a permit for quantities above certain thresholds). Milk thistle preparations are generally available without prescription in Australia, though this doesn't mean they are without considerations, potential interactions with cytochrome P450 enzyme pathways have been noted in the pharmacological literature, and anyone taking prescribed medicines should speak to a pharmacist or GP before adding any complementary preparation.

Good Manufacturing Practice requirements apply to the manufacture of listed complementary medicines in Australia, providing a quality floor; but GMP does not itself validate the efficacy of the product. These are separate questions.

Traditional use versus clinical evidence: where they diverge

This is the part I find genuinely interesting, and where I'd gently push back on both the enthusiastic herbalism end and the reflexively dismissive sceptic end of the conversation. Traditional use is a legitimate data source. Two thousand years of documented application across multiple independent cultures (Mediterranean, Ayurvedic, Western herbal) gives you signal worth examining. It doesn't give you proof of efficacy by modern clinical standards, but it does give researchers a reasonable rationale for investing in proper trials.

What traditional use cannot do is substitute for well-designed human trials with appropriate controls, adequate sample sizes, and pre-registered outcomes. The milk thistle literature has too many small, short-duration, unregistered trials. That's a research infrastructure problem as much as anything else, phytomedicine research is chronically underfunded compared to pharmaceutical drug development, and standardisation challenges make multicenter trials difficult. I reckon this is the main reason the evidence base looks weaker than it might otherwise, not because the plant is necessarily without interesting biochemistry, but because the trials needed to demonstrate it rigorously haven't been done at scale.

Honestly, I'd like to see a well-powered, pre-registered trial using a properly characterised, bioavailability-enhanced silymarin preparation. Until that exists, the evidence for milk thistle remains preliminary; interesting, historically grounded, mechanistically plausible in parts, but not yet demonstrated to a standard that would satisfy a regulatory evidentiary threshold for a specific therapeutic indication.

The plant is still worth knowing. Its chemistry is genuinely unusual, its history is long and consistent, and the research programme around it has produced real scientific insights about flavonolignan biochemistry. But knowing a plant well means knowing what we don't know about it too.

Sources

• Listed Medicines Evidence Guidelines, Therapeutic Goods Administration (TGA)
• Milk Thistle: Effects on Liver Disease and Cirrhosis, National Center for Complementary and Integrative Health / NCBI Bookshelf
• Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years; Molecules, NCBI PMC
• Complementary Medicines Regulatory Framework, Therapeutic Goods Administration (TGA)

, Naomi Ellison, Botanical & phytomedicine writer